feeds.bloomberg.com · Sep 2, 2026
Lilly to Buy Merida for $2.88B in Autoimmune Push
Bloomberg's Michelle Davis joins Dani Burger on "Bloomberg Deals." Eli Lilly plans to buy Merida Biosciences Inc.
for as much as $2.88 billion in cash to expand in autoimmune and allergic diseases, part of an effort to build beyond the weight-loss and diabetes markets that made it the largest pharmaceutical company in the world.
More on Growium
- coindesk.comKraken parent Payward delays IPO to second quarter of 2027 at earliest→
- marketwatch.comHPE follows in Dell’s footsteps as it rides the AI server boom to a big earnings beat→
- marketwatch.comStocks close higher as Treasury yields slip; oil prices settle at 6-week high→
- marketwatch.comSnowflake’s stock soars as the company blows away estimates with its AI-fueled forecast→
- cnbc.com10-year U.S. Treasury yield hits highest level since November 2023→
- feeds.bloomberg.comAI Investments, Record M&A, Angels Sold | Bloomberg Deals 9/2/2026→